4.8 Review

Dissecting and rebuilding the glioblastoma microenvironment with engineered materials

Journal

NATURE REVIEWS MATERIALS
Volume 4, Issue 10, Pages 651-668

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41578-019-0135-y

Keywords

-

Funding

  1. National Science Foundation
  2. National Institutes of Health (Ruth L. Kirschstein Predoctoral Individual National Research Service Award) [F31CA228317]
  3. National Institutes of Health (Ruth L. Kirschstein Postdoctoral Individual National Research Service Award) [F32CA221366, R21EB025017, R01GM122375, R01DK118940, R01CA227136]
  4. European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [752097]
  5. Marie Curie Actions (MSCA) [752097] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

Glioblastoma (GBM) is the most aggressive and common form of primary brain cancer. Several decades of research have provided great insight into GBM progression; however, the prognosis remains poor, with a median patient survival time of similar to 15 months. The tumour microenvironment (TME) of GBM plays a crucial role in mediating tumour progression and thus is being explored as a therapeutic target. Progress in the development of treatments targeting the TME is currently limited by a lack of model systems that can accurately recreate the distinct extracellular matrix composition and anatomic features of the brain, such as the blood-brain barrier and axonal tracts. Biomaterials can be applied to develop synthetic models of the GBM TME to mimic physiological and pathophysiological features of the brain, including cellular and extracellular matrix composition, mechanical properties and topography. In this Review, we summarize key features of the GBM microenvironment and discuss different strategies for the engineering of GBM TME models, including 2D and 3D models featuring chemical and mechanical gradients, interfaces and fluid flow. Finally, we highlight the potential of engineered TME models as platforms for mechanistic discovery and drug screening, as well as preclinical testing and precision medicine.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available